DPP4 and diabetes mellitus: However, in the absence of an active comparator generally regarded as cardiovascularly neutral, such as DPP‐4 inhibitors, it remains unclear whether low‐affinity sulfonylureas exert neutral effects and whether high‐affinity sulfonylureas increase cardiovascular risk in patients with diabetes.